ProposalWorkspaceFederal OpportunitiesDepartment of Defense

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Active HT9402-27-Q-9101 SolicitationDefense Health Agency (DHA)
The full text, documents and contacts of this bid come with a ProposalWorkspace plan.Get started

At a glance

Defense Health Agency of Defense Health Agency (DHA) posted this Solicitation on Nov 12, 2026. Responses are due Dec 7, 2026. NAICS 325412 (Pharmaceutical Preparation Manufacturing), product or service code 6505 (Drugs and Biologicals). Place of performance: Texas 78230. Solicitation number HT9402-27-Q-9101.

Solicitation details

General information

Solicitation number
HT9402-27-Q-9101
Notice type
Solicitation
Place of performance
Texas 78230

Classification

NAICS
325412Pharmaceutical Preparation Manufacturing
Product or service
6505Drugs and Biologicals

Agency

Department
Department of Defense
Sub-tier
Defense Health Agency (DHA)
Office
Defense Health Agency

Description

From SAM.gov

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed:

a. Ophthalmic - Dry Eye

  • Cequa
  • Eysuvis
  • Miebo
  • Tryptyr
  • Tyrvaya
  • Verkazia
  • Vevye
  • Xiidra

b. Testosterone Replacement Therapy - Orals

  • Jatenzo
  • Kyzatrex
  • Tlando

The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.

Documents

6 files

Subscribe to download these 6 files.

  • FAR 52-225-6-Certificate.pdf
    645 KB · Nov 12, 2026
    Download
  • Feb 2027 PandT Meeting Reporting.xlsx
    190 KB · Nov 12, 2026
    Download
  • NDC Price List FAQ Class Review.pdf
    227 KB · Nov 12, 2026
    Download
  • PL - Ophthalmic - Dry Eye.xlsx
    44 KB · Nov 12, 2026
    Download
  • PL - Testosterone Replacement Therapy - Orals.xlsx
    45 KB · Nov 12, 2026
    Download
  • RFQ HT9402-27-Q-9101.pdf
    925 KB · Nov 12, 2026
    Download

Similar open bids

Same NAICS 325412

More from Defense Health Agency (DHA)

Open bids, other NAICS codes